What is OVID's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.48B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OVID?

P/E (TTM) is n/a and 52-week range is $1.18 to $3.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OVID figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OVID?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-1.65B, EPS (TTM) near $-0.25 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ovid Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 186.6M shares outstanding, ISIN US6904691010 when available from company profile and filing metadata.

Ovid Therapeutics Inc

$OVID

Health Care · Biotechnology

IR Run Scenarios

$2.46

+5.13%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Employees

Website

ovidrx.com/

IPO

2017-05-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)